(Q36166577)

12 August 2017

1 reference

title

Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis (English)

1 reference

12 August 2017

0 references

1 reference

1 reference

5

Hans-Peter Hartung

1 reference

12 August 2017

2

Olaf Stüve

1 reference

12 August 2017

3

Bernd Kieseier

1 reference

12 August 2017

Bernhard Hemmer

1

1 reference

PubMed ID

15963443

12 August 2017

Huub Schellekens

series ordinal

4

1 reference

PubMed ID

15963443

12 August 2017

language of work or name

1 reference

1 July 2005

1 reference

12 August 2017

1 reference

12 August 2017

4

1 reference

12 August 2017

7

1 reference

12 August 2017

403-412

1 reference

Selection events operating at various stages in B cell development

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Clonal selection and learning in the antibody system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Bioequivalence and the immunogenicity of biopharmaceuticals

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Resistance to Recombinant Interferon Alfa-2a in Hairy-Cell Leukemia Associated with Neutralizing Anti-Interferon Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Pure red-cell aplasia and epoetin therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Current disease-modifying therapies in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

A comparative study of the relative bioavailability of different interferon beta preparations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Statistical approaches to assessing the effects of neutralizing antibodies: IFNbeta-1b in the pivotal trial of relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

The measurement of antibodies binding to IFNβ in MS patients treated with IFNβ

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Neutralising antibodies to interferon beta during the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Evolution of interferon-beta binding antibodies in MS patients may predict development of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Epitope specificity of neutralizing antibodies against IFN-beta

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Antibodies that neutralize human beta interferon biologic activity recognize a linear epitope: analysis by synthetic peptide mapping

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Chemical mutagenesis of human interferon-beta: construction, expression in E. coli, and biological activity of sodium bisulfite-induced mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Immunoregulation and blocking antibodies induced by interferon beta treatment in MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Strategies to treat and prevent the development of neutralizing anti-interferon-β antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Pharmacological methods to overcome IFN-beta antibody formation in the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Rationally engineered therapeutic proteins with reduced immunogenicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970117-4

7 January 2021

10.1016/S1474-4422(05)70117-4

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15963443